Robert Buchanan is a Psychiatry physician affiliated with The University of Texas at Austin. OpenAlex indexes 146 publications with 2,415 citations (h-index 28); ClinicalTrials.gov lists 14 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3705 Medical Pkwy Ste 520
Austin, TX 787051029
Telephone
512-298-3637Provider last certified this registry record 30 Sept 2025.
Clinical trials
- Treating Refractory Schizophrenia With rTMS
Sponsor: Seton Healthcare Family
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ACADIA Pharmaceuticals IncProgram year20251 payment
- Abbott LaboratoriesProgram year202413 payments
- Saluda Medical Americas, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
94.8%SSRI15.3%Sertraline Hcl46%Trazodone Hcl24%Escitalopram Oxalate17%Fluoxetine Hcl7%Paroxetine Hcl5%Part D<11 patientsBenzodiazepine12.1%Clonazepam34%Alprazolam26%Lorazepam22%Temazepam9%Alprazolam Er9%Part D<11 patients+ 16 more classes in this area
Hormonal (systemic)
3%l-Triiodothyronine2.3%Liothyronine Sodium100%Part D<11 patientsl-Thyroxine0.7%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
1.6%Beta blocker0.9%Propranolol Hcl100%Part D<11 patientsalpha-Adrenergic Blocker0.7%Prazosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–1999 per NIH RePORTER. The latest:
- ANALYSES OF PUBLIC POLICIES--COVERAGE OF HIV DRUGS
Texas A&m University Health Science Ctr
FY1999R03HS009819
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Warach, MD, PhD
The University of Texas at Austin
Elizabeth Matsui, MD
The University of Texas at Austin
Jorge Almeida, MD
The University of Texas at Austin
George Rodgers, MD
The University of Texas at Austin
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”